Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that the Company will present and conduct 1-on-1 meetings with investors at the 2022 Wells Fargo Healthcare Conference and H.C. Wainwright 24^th Annual Global Investment Conference.

2022 Wells Fargo Healthcare Conference

Date: Friday, September 9, 2022

Time: 8:00 a.m. ET

Speaker: Adelene Perkins, Chief Executive Officer

Format: In-person fireside chat and 1-on-1 meetings

Webcast Registration Link

H.C. Wainwright 24^th Annual Global Investment Conference

Date: Monday, September 12, 2022

Time: Presentation available at 7:00 a.m. ET

Speaker: Adelene Perkins, Chief Executive Officer

Format: Virtual company presentation and 1-on-1 meetings

Webcast Registration Link

A replay of the presentations will be available in the Investors/Media section of Infinity's website at www.infi.com for 90 days following the events.

About Infinity and Eganelisib

Infinity Pharmaceuticals, Inc. (“Infinity” or the “Company”), is a clinical-stage biotechnology company developing eganelisib (IPI-549), a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which is designed to address a fundamental biologic mechanism of immune suppression in cancer in multiple clinical studies. MARIO-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with Tecentriq^® and Abraxane^® in front-line TNBC and in combination with Tecentriq and Avastin^® in front-line RCC. MARIO-275 is a randomized, controlled combination study of eganelisib combined with Opdivo^® in I/O naïve urothelial cancer. For more information on Infinity, please refer to Infinity's website at www.infi.com.

Opdivo^® is a registered trademark of Bristol Myers Squibb.

Tecentriq^® is a registered trademark of Genentech, Inc.

Abraxane^® is a registered trademark of Abraxis BioScience, LLC., a wholly owned subsidiary of Bristol Myers Squibb Company.

Avastin^® is a registered trademark of Genentech, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220831005151/en/